21 results on '"Gordon, Stuart C."'
Search Results
2. Correction to: Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis
3. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease
4. The Health Care Burden of Hepatic Encephalopathy
5. Antiviral Treatment and Response are Associated With Lower Risk of Dementia Among Hepatitis C Virus-Infected Patients
6. Primary Biliary Cholangitis: Epidemiology, Diagnosis, and Presentation
7. Sequential PegIFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B
8. LBP-040 Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interimresults for 2 years from the ASSURE study
9. WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment
10. SAT-438 Fatigue is an Important Driver of Work Productivity Loss and Impairment of Patient-Reported Outcomes (PROs) among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
11. Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis.
12. African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis.
13. Persistent pruritus associated with worse quality of life in patients with chronic hepatitis.
14. Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
15. OS-019 Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated liver cirrhosis in the open-label, long-term ASSURE safety study: interim results
16. Mo1594 EVALUATION OF RACIAL DIFFERENCES IN ALKALINE PHOSPHATASE TRAJECTORY AND ANTI-MITOCHONDRIAL ANTIBODY POSITIVITY PRIOR TO DIAGNOSIS OF PRIMARY BILIARY CHOLANGITIS
17. 3 EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS IN THE ASSURE STUDY: INTERIM RESULTS
18. Featured Cover.
19. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
20. Beyond the Surface: Unveiling Hidden Hurdles to Primary Biliary Cholangitis Care.
21. Persistent pruritus associated with worse quality of life in patients with chronic hepatitis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.